Development of autoantibodies to T cell clonotypic structures in a liver-kidney allograft recipient

Transplantation. 1993 Jul;56(1):212-6. doi: 10.1097/00007890-199307000-00039.

Abstract

To elucidate the mechanism of human liver allograft rejection and acceptance, T cell clones were established from liver biopsies of a liver-kidney transplant recipient during a rejection episode. Five of the clones were characterized and found to be CD4+, alpha/beta positive T cells that proliferated specifically to the mismatched donor HLAs. Using an immunofluorescence assay, it was observed that three of these clones were recognized by autologous antibodies developed during the post-transplant period between 18 months and the end of the testing period of 36 months. Furthermore, by capping experiments, it was determined that these antibodies were recognizing the CD3-TCR complex. This was confirmed by immunoprecipitation and sequential immunoprecipitation followed by SDS-PAGE and autoradiography of lysates of radiolabeled T cell clones. Thus, our data indicate that donor-reactive T cells infiltrate into the liver allograft during rejection episodes, and that autologous antibodies reactive to the CD3-TCR complex of these cells are developed in the post-transplant period. These results support the hypothesis that the development of auto-antibodies directed against or cross-reactive to the clonotypic structures of the donor-reactive lymphocytes may play an important role in the down-regulation of the immune response against the allograft.

Publication types

  • Case Reports
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Autoantibodies / biosynthesis*
  • Autoantibodies / blood
  • CD3 Complex / analysis
  • Cells, Cultured
  • Clone Cells
  • Female
  • Flow Cytometry
  • Humans
  • Immunoglobulin G / blood
  • Kidney Transplantation / immunology*
  • Kidney Transplantation / pathology
  • Liver Transplantation / immunology*
  • Liver Transplantation / pathology
  • T-Lymphocytes / immunology*
  • Transplantation, Homologous

Substances

  • Autoantibodies
  • CD3 Complex
  • Immunoglobulin G